APONTIS PHARMA AG
APONTIS PHARMA builds on strong position and profitability in first half of 2021 – preliminary figures and forecast confirmed
DGAP-News: APONTIS PHARMA AG
/ Key word(s): Half Year Results/Half Year Report
APONTIS PHARMA builds on strong position and profitability in first half of 2021 – preliminary figures and forecast confirmed
APONTIS PHARMA grew in the 6-month period of 2021 against the general market trend in the pharmaceutical industry by posting a 36% increase in revenue to EUR 24.0 million. Single Pill revenues were the main growth drivers with a significant increase of 83% to EUR 14.0 million and increased the share of Single Pills in total revenues to 58% (H1 2020: 43%). Cost of materials increased significantly slower than the revenues volume. Earnings before interest, taxes, depreciation and amortization (EBITDA adjusted), which are mainly adjusted for IPO costs, improved at Group level by EUR 4.3 million to EUR 2.8 million (H1 2020: negative). APONTIS PHARMA has a solid asset and financial position with an equity ratio of 72%, liquid assets of EUR 30.5 million and liabilities of EUR 7.6 million. For financial year 2021, the Management Board continues to expect revenues of EUR 48.5 million and EBITDA adjusted of EUR 5.5 million.
APONTIS PHARMA AG’s 2021 half-year report is available on the company’s website at ir.apontis-pharma.de. CEO Karlheinz Gast and CPO Thomas Milz will explain the results of the first half of 2021 in a webcast presentation today, 11 August 2021, 14.00 CEST. The presentation will be held in English. Please register in time to participate at: APONTIS PHARMA Half Year Report 2021 – Webcast/Teleconference. The accompanying presentation will also be available on the company’s website prior to the start. APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three patent-free active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases as well as diabetes and respiratory diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. Driven by the more effective therapeutic success demonstrated in the START study, APONTIS PHARMA’s focus has been on Single Pills since October 2020. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe’s leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de. Investor Relations CROSS ALLIANCE communication GmbH
11.08.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | APONTIS PHARMA AG |
Alfred-Nobel-Str. 10 | |
40789 Monheim | |
Germany | |
E-mail: | info@apontis-pharma.de |
Internet: | https://apontis-pharma.de/ |
ISIN: | DE000A3CMGM5 |
WKN: | A3CMGM |
Listed: | Regulated Unofficial Market in Frankfurt (Scale) |
EQS News ID: | 1225409 |
End of News | DGAP News Service |